老年人呼吸道合胞病毒的疾病负担和防治进展
Disease Burden and Advances in Prevention and Treatment of Respiratory Syncytial Virus in Older Adults
DOI: 10.12677/acm.2026.161292, PDF,    科研立项经费支持
作者: 王红梅, 黄文祥*：重庆医科大学附属第一医院老年医学科，老年疾病研究与转化实验室，重庆
关键词: 呼吸道合胞病毒；老年人；负担；疫苗；治疗；Respiratory Syncytial Virus； Older Adults； Burden； Vaccine； Treatment
摘要: 呼吸道合胞病毒(respiratory syncytial virus, RSV)长期以来被视为婴幼儿呼吸道感染的重要病原体，然而越来越多的证据表明RSV感染已日益成为老年人下呼吸道疾病住院和死亡的重要原因之一，给老年人群带来了沉重的疾病负担。随着人口老龄化的加剧，老年人的RSV感染值得密切关注。本文综述了RSV在老年人中的流行趋势，强调了RSV感染给老年人带来的巨大疾病负担，深入分析了这类群体被低估的疾病负担背后的原因。同时还总结了RSV的疫苗和药物的研究进展以及当前的防控策略，旨在为临床实践和公共卫生决策提供参考。
Abstract: Respiratory syncytial virus (RSV) has long been recognized as a significant pathogen causing respiratory tract infections in infants and young children. However, mounting evidence indicates that RSV infections have increasingly become a major cause of lower respiratory tract disease hospitalizations and mortality among the older adults, posing a heavy disease burden for the elderly population. With the acceleration of population aging, RSV infections in the older adults warrant close attention. This paper reviews the epidemiological trends of RSV in the older adults, highlights the immense disease burden it imposes on this population, and insightfully analyzes the reasons behind the underestimated disease burden in this group. Additionally, we systematically review the research progress of vaccines and drugs for RSV, as well as current prevention and control strategies, aiming to provide a scientific basis for clinical practice and public health policy-making.
文章引用：王红梅, 黄文祥. 老年人呼吸道合胞病毒的疾病负担和防治进展[J]. 临床医学进展, 2026, 16(1): 2333-2340. https://doi.org/10.12677/acm.2026.161292

参考文献

[1] Kenmoe, S. and Nair, H. (2024) The Disease Burden of Respiratory Syncytial Virus in Older Adults. Current Opinion in Infectious Diseases, 37, 129-136. [Google Scholar] [CrossRef] [PubMed]
[2] Wagatsuma, K., Koolhof, I.S. and Saito, R. (2023) Nonlinear and Multidelayed Effects of Meteorological Drivers on Human Respiratory Syncytial Virus Infection in Japan. Viruses, 15, Article No. 1914. [Google Scholar] [CrossRef] [PubMed]
[3] Liu, P., Xu, M., Cao, L., Su, L., Lu, L., Dong, N., et al. (2021) Impact of COVID-19 Pandemic on the Prevalence of Respiratory Viruses in Children with Lower Respiratory Tract Infections in China. Virology Journal, 18, Article No. 159. [Google Scholar] [CrossRef] [PubMed]
[4] Kim, T. and Choi, S. (2024) Epidemiology and Disease Burden of Respiratory Syncytial Virus Infection in Adults. Infection & Chemotherapy, 56, Article No. 1. [Google Scholar] [CrossRef] [PubMed]
[5] Billard, M., van de Ven, P.M., Baraldi, B., Kragten‐Tabatabaie, L., Bont, L.J. and Wildenbeest, J.G. (2022) International Changes in Respiratory Syncytial Virus (RSV) Epidemiology during the COVID‐19 Pandemic: Association with School Closures. Influenza and Other Respiratory Viruses, 16, 926-936. [Google Scholar] [CrossRef] [PubMed]
[6] Juhn, Y.J., Wi, C., Takahashi, P.Y., Ryu, E., King, K.S., Hickman, J.A., et al. (2023) Incidence of Respiratory Syncytial Virus Infection in Older Adults before and during the COVID-19 Pandemic. JAMA Network Open, 6, e2250634. [Google Scholar] [CrossRef] [PubMed]
[7] 卫小枫, 李茂中, 王怡婷, 等. 北京地区60岁及以上老年人呼吸道合胞病毒感染流行病学和临床特征研究[J]. 中华预防医学杂志, 2024, 58(7): 952-958.
[8] Bardsley, M., Morbey, R.A., Hughes, H.E., Beck, C.R., Watson, C.H., Zhao, H., et al. (2023) Epidemiology of Respiratory Syncytial Virus in Children Younger than 5 Years in England during the COVID-19 Pandemic, Measured by Laboratory, Clinical, and Syndromic Surveillance: A Retrospective Observational Study. The Lancet Infectious Diseases, 23, 56-66. [Google Scholar] [CrossRef] [PubMed]
[9] White, L.J., Waris, M., Cane, P.A., Nokes, D.J. and Medley, G.F. (2005) The Transmission Dynamics of Groups a and B Human Respiratory Syncytial Virus (HRSV) in England & Wales and Finland: Seasonality and Cross-Protection. Epidemiology and Infection, 133, 279-289. [Google Scholar] [CrossRef] [PubMed]
[10] Korsten, K., Adriaenssens, N., Coenen, S., Butler, C., Ravanfar, B., Rutter, H., et al. (2020) Burden of Respiratory Syncytial Virus Infection in Community-Dwelling Older Adults in Europe (RESCEU): An International Prospective Cohort Study. European Respiratory Journal, 57, Article ID: 2002688. [Google Scholar] [CrossRef] [PubMed]
[11] Tseng, H.F., Sy, L.S., Ackerson, B., Solano, Z., Slezak, J., Luo, Y., et al. (2020) Severe Morbidity and Short-and Mid-to Long-Term Mortality in Older Adults Hospitalized with Respiratory Syncytial Virus Infection. The Journal of Infectious Diseases, 222, 1298-1310. [Google Scholar] [CrossRef] [PubMed]
[12] Belongia, E.A., King, J.P., Kieke, B.A., Pluta, J., Al-Hilli, A., Meece, J.K., et al. (2018) Clinical Features, Severity, and Incidence of RSV Illness during 12 Consecutive Seasons in a Community Cohort of Adults ≥ 60 Years Old. Open Forum Infectious Diseases, 5, ofy316. [Google Scholar] [CrossRef] [PubMed]
[13] Papi, A., Ison, M.G., Langley, J.M., Lee, D., Leroux-Roels, I., Martinon-Torres, F., et al. (2023) Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults. New England Journal of Medicine, 388, 595-608. [Google Scholar] [CrossRef] [PubMed]
[14] Wilkinson, T.M.A., Donaldson, G.C., Johnston, S.L., Openshaw, P.J.M. and Wedzicha, J.A. (2006) Respiratory Syncytial Virus, Airway Inflammation, and FEV 1 Decline in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 173, 871-876. [Google Scholar] [CrossRef] [PubMed]
[15] Tin Tin Htar, M., Yerramalla, M.S., Moïsi, J.C. and Swerdlow, D.L. (2020) The Burden of Respiratory Syncytial Virus in Adults: A Systematic Review and Meta-Analysis. Epidemiology and Infection, 148, e48. [Google Scholar] [CrossRef] [PubMed]
[16] Shi, T., Denouel, A., Tietjen, A.K., et al. (2020) Global Disease Burden Estimates of Respiratory Syncytial Virus-Associated Acute Respiratory Infection in Older Adults in 2015: A Systematic Review and Meta-Analysis. The Journal of Infectious Diseases, 222, S577-S583.
[17] Ackerson, B., An, J., Sy, L.S., Solano, Z., Slezak, J. and Tseng, H. (2020) Cost of Hospitalization Associated with Respiratory Syncytial Virus Infection versus Influenza Infection in Hospitalized Older Adults. The Journal of Infectious Diseases, 222, 962-966. [Google Scholar] [CrossRef] [PubMed]
[18] Choi, Y., Hill‐Ricciuti, A., Branche, A.R., Sieling, W.D., Saiman, L., Walsh, E.E., et al. (2021) Cost Determinants among Adults Hospitalized with Respiratory Syncytial Virus in the United States, 2017-2019. Influenza and Other Respiratory Viruses, 16, 151-158. [Google Scholar] [CrossRef] [PubMed]
[19] Peláez, A., Jimeno Ruiz, S., Villarreal, M., Gil, M., Gutiérrez, I., Sanz, M., et al. (2025) Burden and Economic Impact of Respiratory Viral Infections in Adults Aged 60 and Older: A Focus on RSV. Diseases, 13, Article No. 35. [Google Scholar] [CrossRef] [PubMed]
[20] Li, Y., Kulkarni, D., Begier, E., Wahi-Singh, P., Wahi-Singh, B., Gessner, B., et al. (2023) Adjusting for Case Under-Ascertainment in Estimating RSV Hospitalisation Burden of Older Adults in High-Income Countries: A Systematic Review and Modelling Study. Infectious Diseases and Therapy, 12, 1137-1149. [Google Scholar] [CrossRef] [PubMed]
[21] McLaughlin, J.M., Khan, F., Begier, E., Swerdlow, D.L., Jodar, L. and Falsey, A.R. (2022) Rates of Medically Attended RSV among US Adults: A Systematic Review and Meta-Analysis. Open Forum Infectious Diseases, 9, ofac300. [Google Scholar] [CrossRef] [PubMed]
[22] Talbot, H.K. and Falsey, A.R. (2010) The Diagnosis of Viral Respiratory Disease in Older Adults. Clinical Infectious Diseases, 50, 747-751. [Google Scholar] [CrossRef] [PubMed]
[23] Nuwer, R. (2023) Better Awareness of RSV in Older Adults Is Needed to Fight a Growing Burden. Nature, 621, S58-S59. [Google Scholar] [CrossRef] [PubMed]
[24] Allen, K.E., Beekmann, S.E., Polgreen, P., Poser, S., St. Pierre, J., Santibañez, S., et al. (2018) Survey of Diagnostic Testing for Respiratory Syncytial Virus (RSV) in Adults: Infectious Disease Physician Practices and Implications for Burden Estimates. Diagnostic Microbiology and Infectious Disease, 92, 206-209. [Google Scholar] [CrossRef] [PubMed]
[25] Ackerson, B., Tseng, H.F., Sy, L.S., Solano, Z., Slezak, J., Luo, Y., et al. (2018) Severe Morbidity and Mortality Associated with Respiratory Syncytial Virus versus Influenza Infection in Hospitalized Older Adults. Clinical Infectious Diseases, 69, 197-203. [Google Scholar] [CrossRef] [PubMed]
[26] Korsten, K., Adriaenssens, N., Coenen, S., Butler, C.C., Verheij, T.J.M., Bont, L.J., et al. (2021) World Health Organization Influenza-Like Illness Underestimates the Burden of Respiratory Syncytial Virus Infection in Community-Dwelling Older Adults. The Journal of Infectious Diseases, 226, S71-S78. [Google Scholar] [CrossRef] [PubMed]
[27] Rozenbaum, M.H., Begier, E., Kurosky, S.K., Whelan, J., Bem, D., Pouwels, K.B., et al. (2023) Incidence of Respiratory Syncytial Virus Infection in Older Adults: Limitations of Current Data. Infectious Diseases and Therapy, 12, 1487-1504. [Google Scholar] [CrossRef] [PubMed]
[28] Griffiths, C., Drews, S.J. and Marchant, D.J. (2017) Respiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment. Clinical Microbiology Reviews, 30, 277-319. [Google Scholar] [CrossRef] [PubMed]
[29] Falsey, A.R. and Walsh, E.E. (2023) Respiratory Syncytial Virus Prefusion F Vaccine. Cell, 186, 3137-3137.e1. [Google Scholar] [CrossRef] [PubMed]
[30] Ison, M.G., Papi, A., Athan, E., Feldman, R.G., Langley, J.M., Lee, D., et al. (2025) Efficacy, Safety, and Immunogenicity of the AS01(E)-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults over Three Respiratory Syncytial Virus Seasons (AReS-Vi-006): A Multicentre, Randomised, Observer-Blinded, Placebo-Controlled, Phase 3 Trial. The Lancet Respiratory Medicine, 13, 517-529. [Google Scholar] [CrossRef] [PubMed]
[31] Walsh, E.E., Pérez Marc, G., Falsey, A.R., Jiang, Q., Eiras, D., Patton, M., et al. (2024) RENOIR Trial—RSVpreF Vaccine Efficacy over Two Seasons. New England Journal of Medicine, 391, 1459-1460. [Google Scholar] [CrossRef] [PubMed]
[32] Walsh, E.E., Pérez Marc, G., Zareba, A.M., Falsey, A.R., Jiang, Q., Patton, M., et al. (2023) Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults. New England Journal of Medicine, 388, 1465-1477. [Google Scholar] [CrossRef] [PubMed]
[33] Wilson, E., Goswami, J., Baqui, A.H., Doreski, P.A., Perez-Marc, G., Zaman, K., et al. (2023) Efficacy and Safety of an mRNA-Based RSV Pref Vaccine in Older Adults. New England Journal of Medicine, 389, 2233-2244. [Google Scholar] [CrossRef] [PubMed]
[34] US CDC (2025) Weekly RSV Vaccination Dashboard. RSVVaxView|CDC.
https://www.cdc.gov/rsvvaxview/dashboard/
[35] 成人急性呼吸道病毒感染急诊诊疗专家共识组. 成人急性呼吸道病毒感染急诊诊疗专家共识[J]. 中华急诊医学杂志, 2021, 30(12): 1417-1428.
[36] Manothummetha, K., Mongkolkaew, T., Tovichayathamrong, P., Boonyawairote, R., Meejun, T., Srisurapanont, K., et al. (2023) Ribavirin Treatment for Respiratory Syncytial Virus Infection in Patients with Haematologic Malignancy and Haematopoietic Stem Cell Transplant Recipients: A Systematic Review and Meta-Analysis. Clinical Microbiology and Infection, 29, 1272-1279. [Google Scholar] [CrossRef] [PubMed]
[37] Tejada, S., Martinez-Reviejo, R., Karakoc, H.N., Peña-López, Y., Manuel, O. and Rello, J. (2022) Ribavirin for Treatment of Subjects with Respiratory Syncytial Virus-Related Infection: A Systematic Review and Meta-Analysis. Advances in Therapy, 39, 4037-4051. [Google Scholar] [CrossRef] [PubMed]
[38] Krilov, L.R. and Roberts, N.J. (2022) Respiratory Syncytial Virus (RSV) Update. Viruses, 14, Article No. 2110. [Google Scholar] [CrossRef] [PubMed]
[39] Gatt, D., Martin, I., AlFouzan, R. and Moraes, T.J. (2023) Prevention and Treatment Strategies for Respiratory Syncytial Virus (RSV). Pathogens, 12, Article No. 154. [Google Scholar] [CrossRef] [PubMed]
[40] Lee, N., Lui, G.C.Y., Wong, K.T., Li, T.C.M., Tse, E.C.M., Chan, J.Y.C., et al. (2013) High Morbidity and Mortality in Adults Hospitalized for Respiratory Syncytial Virus Infections. Clinical Infectious Diseases, 57, 1069-1077. [Google Scholar] [CrossRef] [PubMed]
[41] Zhao, S., Shang, Y., Yin, Y., Zou, Y., Xu, Y., Zhong, L., et al. (2024) Ziresovir in Hospitalized Infants with Respiratory Syncytial Virus Infection. New England Journal of Medicine, 391, 1096-1107. [Google Scholar] [CrossRef] [PubMed]
[42] Zhang, H., Zhao, W., Zhang, X., Zhang, L., Guo, R., Huang, H., et al. (2025) Efficacy and Safety of Ziresovir in Hospitalised Infants Aged 6 Months or Younger with Respiratory Syncytial Virus Infection in China: Findings from a Phase 3 Randomised Trial with 24-Month Follow-up. The Lancet Child & Adolescent Health, 9, 325-336. [Google Scholar] [CrossRef] [PubMed]
[43] 浙江省疾病预防控制中心, 浙江省传染病疫苗与预防控制研究重点实验室, 复旦大学附属儿科医院国家儿童医学中心上海, 等. 人呼吸道合胞病毒感染监测与防控专家共识(2023年) [J]. 中华临床感染病杂志, 2023, 16(5): 337-353.
[44] 中国医学科学院北京协和医学院群医学及公共卫生学院, 中国医药卫生文化协会疫苗与健康分会, 专家组中国老年人群人呼吸道合胞病毒感染防控的关键问题专家共识. 中国老年人群人呼吸道合胞病毒感染防控的关键问题专家共识[J]. 中华预防医学杂志, 2025, 59(8): 1183-1195.

为你推荐